Clinical trial
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
NCT00157274 · Latin American Cooperative Onco-Haematology Group - Peru, Other · Unknown status
Key facts
| NCT number | NCT00157274 |
|---|---|
| Title | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome |
| Official title | Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome |
| Lead sponsor | Latin American Cooperative Onco-Haematology Group - Peru, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mycosis Fungoides, Sezary Syndrome |
| Intervention type | Drug |
| Interventions | alemtuzumab |
| Enrollment | 20 |
| Start date | Jul 1, 2005 |
| Completion | Jul 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Apr 3, 2007 |
| Countries | Peru |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: